Skip to main content
. 2023 Feb 6;49:110–118. doi: 10.1016/j.euros.2022.12.015

Fig. 1.

Fig. 1

Trends in first-line systemic treatment use for patients with metastatic renal cell carcinoma. Q = quarter; TKI = tyrosine kinase inhibitor.